Literature DB >> 33776923

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.

Krijn K Dijkstra1,2, José G van den Berg3, Fleur Weeber1,2, Joris van de Haar1,2, Arno Velds4, Sovann Kaing1,2, Dennis D G C Peters5, Ferry A L M Eskens6, Derk-Jan A de Groot7, Margot E T Tesselaar8, Emile E Voest1,2.   

Abstract

Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a poorly understood disease with limited treatment options. A better understanding of this disease would greatly benefit from the availability of representative preclinical models. Here, we present the potential of tumor organoids, three-dimensional cultures of tumor cells, to model GEP-NEC. We established three GEP-NEC organoid lines, originating from the stomach and colon, and characterized them using DNA sequencing and immunohistochemistry. Organoids largely resembled the original tumor in expression of synaptophysin, chromogranin and Ki-67. Models derived from tumors containing both neuroendocrine and non-neuroendocrine components were at risk of overgrowth by non-neuroendocrine tumor cells. Organoids were derived from patients treated with cisplatin and everolimus and for the three patients studied, organoid chemosensitivity paralleled clinical response. We demonstrate the feasibility of establishing NEC organoid lines and their potential applications. Organoid culture has the potential to greatly extend the repertoire of preclinical models for GEP-NEC, supporting drug development for this difficult-to-treat tumor type.
Copyright © 2021 Dijkstra, van den Berg, Weeber, van de Haar, Velds, Kaing, Peters, Eskens, de Groot, Tesselaar and Voest.

Entities:  

Keywords:  disease modeling; extrapulmonary neuroendocrine carcinoma; gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC); organoids; pre-clinical models

Mesh:

Substances:

Year:  2021        PMID: 33776923      PMCID: PMC7991829          DOI: 10.3389/fendo.2021.627819

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  40 in total

1.  Extra-Pulmonary Neuroendocrine Carcinomas: A Population-Based Study in the Netherlands.

Authors:  Jan Maarten van der Zwan; Sabine Siesling; Loes van Velthuysen; Thera Links; Annemiek Walenkamp; Margot Tesselaar
Journal:  Neuroendocrinology       Date:  2018-04-14       Impact factor: 4.914

2.  The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.

Authors:  G A Cirkel; F Weeber; S Bins; C G M Gadellaa-van Hooijdonk; E van Werkhoven; S M Willems; M van Stralen; W B Veldhuis; I Ubink; N Steeghs; M J de Jonge; M H G Langenberg; J H M Schellens; S Sleijfer; M P Lolkema; E E Voest
Journal:  Ann Oncol       Date:  2016-05-27       Impact factor: 32.976

3.  Organoid models of human and mouse ductal pancreatic cancer.

Authors:  Sylvia F Boj; Chang-Il Hwang; Lindsey A Baker; Iok In Christine Chio; Dannielle D Engle; Vincenzo Corbo; Myrthe Jager; Mariano Ponz-Sarvise; Hervé Tiriac; Mona S Spector; Ana Gracanin; Tobiloba Oni; Kenneth H Yu; Ruben van Boxtel; Meritxell Huch; Keith D Rivera; John P Wilson; Michael E Feigin; Daniel Öhlund; Abram Handly-Santana; Christine M Ardito-Abraham; Michael Ludwig; Ela Elyada; Brinda Alagesan; Giulia Biffi; Georgi N Yordanov; Bethany Delcuze; Brianna Creighton; Kevin Wright; Youngkyu Park; Folkert H M Morsink; I Quintus Molenaar; Inne H Borel Rinkes; Edwin Cuppen; Yuan Hao; Ying Jin; Isaac J Nijman; Christine Iacobuzio-Donahue; Steven D Leach; Darryl J Pappin; Molly Hammell; David S Klimstra; Olca Basturk; Ralph H Hruban; George Johan Offerhaus; Robert G J Vries; Hans Clevers; David A Tuveson
Journal:  Cell       Date:  2014-12-31       Impact factor: 41.582

4.  An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Authors:  Oded Kopper; Chris J de Witte; Kadi Lõhmussaar; Jose Espejo Valle-Inclan; Nizar Hami; Lennart Kester; Anjali Vanita Balgobind; Jeroen Korving; Natalie Proost; Harry Begthel; Lise M van Wijk; Sonia Aristín Revilla; Rebecca Theeuwsen; Marieke van de Ven; Markus J van Roosmalen; Bas Ponsioen; Victor W H Ho; Benjamin G Neel; Tjalling Bosse; Katja N Gaarenstroom; Harry Vrieling; Maaike P G Vreeswijk; Paul J van Diest; Petronella O Witteveen; Trudy Jonges; Johannes L Bos; Alexander van Oudenaarden; Ronald P Zweemer; Hugo J G Snippert; Wigard P Kloosterman; Hans Clevers
Journal:  Nat Med       Date:  2019-04-22       Impact factor: 53.440

5.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Authors:  H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

6.  Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.

Authors:  Catharina M Korse; Babs G Taal; Marie-Louise F van Velthuysen; Otto Visser
Journal:  Eur J Cancer       Date:  2013-01-23       Impact factor: 9.162

7.  Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract.

Authors:  Daniela Furlan; Roberta Cerutti; Silvia Uccella; Stefano La Rosa; Elena Rigoli; Anna Genasetti; Carlo Capella
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

8.  Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.

Authors:  F Favero; T Joshi; A M Marquard; N J Birkbak; M Krzystanek; Q Li; Z Szallasi; A C Eklund
Journal:  Ann Oncol       Date:  2014-10-15       Impact factor: 32.976

Review 9.  Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.

Authors:  Kenta Kawasaki; Masayuki Fujii; Toshiro Sato
Journal:  Dis Model Mech       Date:  2018-02-26       Impact factor: 5.758

10.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.

Authors:  Marc Hafner; Mario Niepel; Mirra Chung; Peter K Sorger
Journal:  Nat Methods       Date:  2016-05-02       Impact factor: 28.547

View more
  4 in total

1.  A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models.

Authors:  Dharaminder Singh; Sudhir P Deosarkar; Elaine Cadogan; Vikki Flemington; Alysha Bray; Jingwen Zhang; Ronald S Reiserer; David K Schaffer; Gregory B Gerken; Clayton M Britt; Erik M Werner; Francis D Gibbons; Tomasz Kostrzewski; Christopher E Chambers; Emma J Davies; Antonio Ramos Montoya; Jacqueline H L Fok; David Hughes; Kristin Fabre; Matthew P Wagoner; John P Wikswo; Clay W Scott
Journal:  PLoS Biol       Date:  2022-05-26       Impact factor: 9.593

2.  Human Immunocompetent Model of Neuroendocrine Liver Metastases Recapitulates Patient-Specific Tumour Microenvironment.

Authors:  Ewald Jan Doornebal; Nicola Harris; Antonio Riva; Ravi Jagatia; Michail Pizanias; Andreas Prachalias; Krishna Menon; Melissa Preziosi; Ane Zamalloa; Rosa Miquel; Yoh Zen; Michael Robert Orford; Simon Eaton; Nigel Heaton; John Ramage; Elena Palma; Rajaventhan Srirajaskanthan; Shilpa Chokshi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-13       Impact factor: 6.055

3.  RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence.

Authors:  Joseph L Regan; Dirk Schumacher; Stephanie Staudte; Andreas Steffen; Ralf Lesche; Joern Toedling; Thibaud Jourdan; Johannes Haybaeck; Dominik Mumberg; David Henderson; Balázs Győrffy; Christian R A Regenbrecht; Ulrich Keilholz; Reinhold Schäfer; Martin Lange
Journal:  iScience       Date:  2021-05-24

Review 4.  New Developments in Gastric Neuroendocrine Neoplasms.

Authors:  Klaire Exarchou; Nathan A Stephens; Andrew R Moore; Nathan R Howes; D Mark Pritchard
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.